Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jan 10;17:15–37. doi: 10.2147/DDDT.S385981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Zhang et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Glabridin ameliorates the activity of Wnt/β-catenin signaling. Binding of Wnt protein to Frizzled may activate Wnt/β-catenin signaling by recruiting Axin, CK1, Dv1, and GSK-3β. However, SFRPs can negatively regulate Wnt/β-catenin signaling by abolishing Wnts, forming inactive complexes with Frizzled receptors. Activation of Wnt/β-catenin signaling induces inactivation of GSK-3β, stability of β-catenin, and nuclear translocation of β-catenin, which binds to TCF4 and LEF-1 and promotes the transcriptional expression of target genes, such as MMPs, c-Myc, and Cyclin D1. Glabridin exhibits inhibitory activity against β-catenin-mediated target genes expression.